All data are based on the daily closing price as of April 28, 2025
l
Lumosa Therapeutics
6535.TWO
4.88 USD
0.05
+1.04%
Overview
Last close
4.88 usd
Market cap
805.46M usd
52 week high
12.06 usd
52 week low
1.89 usd
Target price
7.09 usd
Valuation
P/E
N/A
Forward P/E
N/A
Price/Sales
681.558
Price/Book Value
13.871
Enterprise Value
775.49M usd
EV/Revenue
642.9091
EV/EBITDA
N/A
Key financials
Revenue TTM
1.21M usd
Gross Profit TTM
545687 usd
EBITDA TTM
-10.88M usd
Earnings per Share
-0.08 usd
Dividend
N/A usd
Total assets
49.09M usd
Net debt
-8.59M usd
About
Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan, Asia, the Americas, and Europe. The company offers Naldebain (LT " 1001), an analgesic injection for severe pain relief after surgery. It is developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that has completed Phase I clinical trial for uremic pruritus; LT6001 that is in pre-clinical trials for neurological disorders; and LT2003, which is in pre-clinical stage for the treatment of oncology. In addition, the company engages in the investment, consulting, service, and transfer of techniques activities. Lumosa Therapeutics Co., Ltd. was incorporated in 2000 and is headquartered in Taipei, Taiwan.